×

Active Biotech AB Interim report January - September 2014

LUND, Sweden, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Laquinimod
· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting
· Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington's disease
· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in the first half of 2016

Tasquinimod
· The Phase III study 10TASQ10 is proceeding according to the original schedule and results are expected in the first half of 2015

ANYARA
· Only out-licensing activities are being conducted

Paquinimod (57-57)
· Only out-licensing activities are being conducted

ISI
· CD selection expected in 2015.

New share issue
· Rights issue totaling approximately SEK 225 million to be approved by the Extraordinary General Meeting on December 1, 2014

Financial summary

MSEK July - Sept. January - Sept. Full Year
2014 2013 2014 2013 2013
Net sales 2.6 107.0 7.5 111.9 116.0
Operating loss -55.7 27.9 -172.8 -128.6 -209.0
Loss for the period -56.6 29.2 -174.5 -130.0 -212.1
Loss per share (SEK) -0.76 0.39 -2.33 -1.77 -2.87
(before and after dilution)

For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com

Active Biotech AB Interim report January - September 2014 http://hugin.info/1002/R/1868647/656843.pdf

HUG#1868647

Source: Active Biotech